Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.